The Mu Type Opioid Receptor pipeline drugs market research report outlays comprehensive information on the Mu Type Opioid Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Mu Type Opioid Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Toxicology, Gastrointestinal, and Dermatology which include the indications Pain, Opium (Opioid) Addiction, Acute Opioid Overdosage, Opioid-Induced Constipation (OIC), Irritable Bowel Syndrome, Diarrhea, Pruritus, and Uremic (Renal) Pruritus. It also reviews key players involved in Mu Type Opioid Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Mu Type Opioid Receptor pipeline targets constitutes close to 138 molecules. Out of which, approximately 127 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 5, 16, 23, 28, 6, 29, and 13 respectively. Similarly, the universities portfolio in Phase I, and Preclinical comprises 1, and 10 molecule.
Mu Type Opioid Receptor overview
Opioid receptor mu 1 (OPRM1) is a type of G protein-coupled receptor (GPCR) that plays a critical role in mediating the analgesic effects of opioids, both endogenous and exogenous. It is widely distributed throughout the central nervous system (CNS), particularly in the spinal cord and brain regions involved in pain processing. MORs are also expressed in peripheral tissues, including the gastrointestinal tract and immune system.
For a complete picture of Mu Type Opioid Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
